Kantorei will perform during the TMEA convention

first_imgHome Local News Education Kantorei will perform during the TMEA convention OCA top 2 were ESL students Previous articlePolice searching for credit card abuse suspectNext articleIMA to host annual symposium admin RELATED ARTICLESMORE FROM AUTHOR Twitter Facebook Pinterest Twitter Associate choir director Ginger Storey directs the Permian High Kantorei varsity choir as they rehearse part of the “Requiem” that they will sing at the Texas Music Educators Association Convention Feb. 14-17 in San Antonio. A preview concert is scheduled for 7:30 p.m. Feb. 5 at the Wagner Noel Performing Arts Center. Pinterest Facebookcenter_img As a tune-up for its performance at the Texas Music Educators Association next month, Kantorei, Permian High School’s varsity choir, will offer a preview concert at 7:30 p.m. Feb. 5 at the Wagner Noel Performing Arts Center, 1310 N. Farm to Market Road 1788.The concert is Feb. 5 and the target date for tickets to go on sale is Jan. 16 through the Wagner Noel, Head Choir Director Aaron Hawley said. Costs will be $10, $15 and $18, depending on seating.Hawley said the choir is inviting local schools to bring their choirs to the concert. Their portion of the ticket cost will be picked up by the University of Texas of the Permian Basin, he said.“That’s really nice of them to do that and help us out,” he added.The TMEA convention is Feb. 14 through Feb. 17. Kantorei will perform at 1:30 p.m. Feb. 15 at the Grand Hyatt hotel in San Antonio. Music will include “Alleluia,” a set from the Mozart Requiem, “Seinn O,” “Even When He is Silent” and “Kanaval.”Kantorei was chosen as a TMEA invited choir, Hawley said.The cost of the trip is $65,000 to $75,000 for about 60 students. Hawley said this is a chance for the community to support the students.“The school district has been very generous and we’re very appreciative of the fact that they’re going to pay a large portion of that, but this concert is to fill in the gaps,” Hawley said. He added that some of the expense is to rent the venue.He added that many community businesses and organizations have stepped up to help.The concert will offer a preview of the San Antonio performance, which is free. Hawley added that many families will make the trip to see the TMEA concert.“TMEA is a massive convention. I think over 30,000 people will be in attendance. Not all of those are choir people. It’s band, choir and orchestra. We will have a good 1,500, 2,000 choir directors who will hear us perform and that really is significant because that helps our community be recognized. It helps Permian High School be recognized within our profession,” Hawley said.“The purpose of those concerts is to kind of set a standard across the state as to, ‘Listen, this is what we should be doing.’ I think there were 12 different organizations that were chosen to perform and that’s high school, middle school and elementary.The selection process goes back to May 2017 when Hawley said more than 150 different choirs submitted audition tracks. Twelve out of those 150 were chosen, he added.“We know it’s an honor for our choir, but we really think it’s really an honor for the whole school, even … the city because a lot of great music has come from West Texas,” along with a lot of TMEA presidents, Hawley said.Within the past five to eight years, Lee High School in Midland and Andrews High School have performed at TMEA.“West Texas has good fine arts. It makes our competitions tough. It makes us have to step up, but we are recognized in the state and this just helps us do that again,” Hawley said.Kennison Vardeman, a 17-year-old senior and choir president, is in his second year in Kantorei. He and fellow 17-year-old senior and choir vice president, Lauren Simmons, are excited about the venture.“It’s just an insane honor that I feel like we don’t even realize how big it is yet,” Vardeman said. “It’s such a crazy once-in-a-lifetime opportunity for us. It’s just awesome to be able to do it my senior year.”Vardeman, who is also in Black Magic at Permian, said preparing for the performance has made the year feel different.“We go at such a fast pace already in this class,” he said. “To go even the extra mile on that all year has definitely made it different. I would definitely say it has sunk in, but not completely.”Simmons also is in her second year as part of Kantorei. She added that this is a chance to show that Permian is about more than just football.“… I think it’s a big honor for all of us in the choir program to be able to be involved in something so big. I think it’s going to be a lot different just because it’s more serious than how we’ve taken just regular choir concerts for our parents. I think it’s just a lot more intense than we’re used to,” Simmons said. By admin – January 12, 2018 WhatsApp Southern Style Potato SaladFruit Salad to Die ForSlap Your Mama It’s So Delicious Southern Squash CasserolePowered By 10 Sec Mama’s Deviled Eggs NextStay WhatsApp Local NewsEducation Kantorei will perform during the TMEA convention Noel earns award Registration set for engineering camp last_img read more

BBB: New Medicare cards on the way — watch out for these scams

first_img Heather Massey is the Regional Director of the Better Business Bureau in the Permian Basin. Check out www.bbb.org or call 563-1880. Facebook BBB Scam TrackerNew Medicare cards are rolling out this month, and they are undergoing a big change to make them more secure from identity thieves. Despite this change, however, scam artists may be using this new rollout to take advantage of unsuspecting Medicare recipients.These new cards, which are being issued to everyone currently enrolled in Medicare are at no cost and will be more secure because they use a “Medicare Beneficiary Identifier” instead of a Social Security number. The delivery of the new cards is staggered, so you will receive your card at a different time than your friends or neighbors. The rollout will continue from now until April 2019.This process will happen automatically, so you do not need to call anyone to get your card. If you are expecting a new card, it is being mailed to the address you have on file with the Social Security Administration. If you need to update your mailing address, you can visit your online account at www.ssa.gov or call 1-800-772-1213.Better Business Bureau serving the Heart of Texas advises you to be on the lookout for scammers hoping to take advantage of any confusion surrounding the launch.How this scam works is you receive a call from a person claiming to work with Medicare. They are allegedly calling about a problem with your new Medicare card. The con artist may say your new card was lost or someone tried to use your ID number. To resolve the situation, the scammer just needs your Social Security number.In another version, the scammer claims you must pay money to receive your new Medicare card. They may ask you for payment information, so they can “complete the process” for you. They may even ask you to mail them your old card.How to Avoid Medicare Scams: Facebook Twitter WhatsApp WhatsApp Pinterest Pinterest Twitter Local NewsBusiness Know how the rollout works. Understand that Medicare isn’t calling consumers about the card switch. If anyone calls and says you need to pay for it, that’s a scam.Never provide personal information to a stranger. Don’t share personal details with anyone who calls you unsolicited. Do not confirm or give out your full name, address, Social Security number or any other personal information.Guard your card. Protect your new card like you would your credit card. While the changes will help cut down on identity theft, thieves can still use it to get medical services.To have a better idea of when your card is coming in, you can check the rollout schedule at www.cms.gov. When you get your new card, be sure to destroy your old one. Shred it instead of tossing it in the trash. If you have a separate Medicare Advantage card, keep that because you’ll still need it for treatment.To report a Medicare scam, or any other type of scam, go to bbb.org/scamtracker. Previous articleA SHARP LIFE: The pros and cons of being an only childNext articleLETTER TO THE EDITOR: Is there a problem at Odessa College? admin BBB: New Medicare cards on the way — watch out for these scams By admin – April 8, 2018 last_img read more

Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration

first_img Facebook Local NewsBusiness By Digital AIM Web Support – February 9, 2021 WhatsApp Twitter Twitter WhatsApp Pinterestcenter_img PHILADELPHIA–(BUSINESS WIRE)–Feb 9, 2021– Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the expansion of its T cell engineered therapy collaboration with the Center for Cellular Immunotherapies (CCI) at the Perelman School of Medicine at the University of Pennsylvania (Penn). Under the terms of the expanded collaboration, Tmunity receives further access and rights to certain platform and manufacturing technologies, as well as the exclusive licensing of a Penn-developed clinical stage asset, a Mesothelin CAR T-cell therapy product. Tmunity has also committed to further funding of T cell engineering research programs at Penn and will receive exclusive rights, subject to certain limitations, to products and technologies resulting from those programs. Tmunity will continue to have certain rights to intellectual property originating from the laboratories of its scientific founders at Penn including: Carl June, MD, Bruce Levine, PhD, and James Riley, PhD. “We are delighted to see the further expansion of our existing scientific and clinical partnership with Penn to bring leading edge T cell engineered medicines to patients with solid tumors. This partnership with Dr. June and the Penn CCI team further expands our access and certain rights to discoveries, clinical programs, cell engineering, and manufacturing at the cutting edge of T cell engineering, including platform technologies in the field, such as safety switches, signaling domains, payload delivery, and novel approaches for cell persistence and durability, ” said Usman ‘Oz’ Azam, President and Chief Executive Officer of Tmunity Therapeutics. “We formed Tmunity to deliver the promise of T cell medicine to patients, bringing together all the essential expertise, technology, and scientific insight to make the next great leap,” said Carl H. June, M.D., Director of the Center for Cellular Immunotherapies at Penn’s Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. “I am tremendously proud of the progress we have accomplished to date and look forward to building on this success in the future.” Tmunity has licensed 4 clinical stage solid tumor CAR-T programs created at Penn and is supporting the further development of several more pipeline candidates through sponsored research agreements with Penn. Drs. June, Levine, Riley, and Chew are all individual equity holders in Tmunity. Penn receives sponsored research funding from Tmunity, and as inventors of some of the licensed technology, Drs. June, Levine, Riley, and Chew, along with Penn, may receive additional financial benefits under the license in the future. Penn is also an investor in the company and holds equity interests. About Tmunity Therapeutics Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical, and manufacturing expertise, and the demonstrated track record of its founders (Carl June, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T-cell medicine. Through the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy and other collaborations, the company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and four programs currently in clinic development. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies. For more information, visit www.tmunity.com and connect with us on social media at @TmunityTx and LinkedIn. View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005080/en/ CONTACT: Media Contact: Lisa Rivero, Syneos Health [email protected] 781-425-4676Investor Relations: Julie Seidel, Stern Investor Relations [email protected] 212-362-1200 KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: Tmunity Therapeutics, Inc. Copyright Business Wire 2021. PUB: 02/09/2021 08:00 AM/DISC: 02/09/2021 08:01 AM http://www.businesswire.com/news/home/20210209005080/en TAGS  Pinterest Facebook Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration Previous articleCodefresh Taps Dan Garfield as Chief Open Source Officer, Strengthening Commitment to Open SourceNext articleXperi’s Connected Radio Solution Renamed DTS AutoStage, Wins 2021 BIG Innovation Award Digital AIM Web Supportlast_img read more

PureFacts beschleunigt Wachstum durch Einstellung eines erfahrenen Fortune 500-Managers als Chief Revenue Officer

first_imgLocal NewsBusiness WhatsApp Twitter Previous articleBNSF Railway Announces 2020 Economic Development ResultsNext articleShaun Russell Conley Digital AIM Web Support WhatsApp Pinterest PureFacts beschleunigt Wachstum durch Einstellung eines erfahrenen Fortune 500-Managers als Chief Revenue Officer Wai-Ming Yu, Chief Revenue Officer, PureFacts Financial Solutionscenter_img Facebook TAGS  By Digital AIM Web Support – February 9, 2021 Pinterest Facebook Twitterlast_img read more

NFL Veteran, Marques Ogden, Joins Forces With an Army Veteran and Grind Oral Care…

first_img Twitter Local NewsBusiness By Digital AIM Web Support – February 9, 2021 SALT LAKE CITY–(BUSINESS WIRE)–Feb 9, 2021– Former NFL offensive linemen, Marques Ogden, officially joins Grind Oral Care as a co-owner. Marques is now in the trenches combating oral care problems! Marques blocked for the Tennessee Titans, Buffalo Bills, Baltimore Ravens, and the Jacksonville Jaguars during his 5-year NFL career. In 2007, Marques launched a construction company, which quickly grew into a multi-million-dollar firm. In 2013, he lost everything, including $2 million in 90 days, due to a bad business deal. However, Marques changed course and persevered against all odds. He rebounded and became an inspirational speaker and executive coach to help others succeed where he had failed. His resilience epitomizes “ The Grind ” never quit culture, making him an invaluable asset to Team Grind. Today, Marques is on Offense, leading marketing efforts as Grind begins a grassroots effort to compete with the Toothpaste Giants. As a former athlete, Marques wants to win; and with his ambition and drive, Grind is ready to compete. He joins forces with U.S Army Special Operations Veteran, Roger Gindlesperger Jr to turn boring commodities into inspirational, game changing products, while helping Veterans. Grind is a new lifestyle toothpaste brand poised to shake things up with innovative products. The first being Grind Toothpaste. A revolutionary charcoal-based toothpaste that whitens and strengthens! Going a step further, Grind differs from all other “fluoride-free” toothpastes by trading fluoride for not one, but two natural alternatives that are backed by real science. The Grind has commenced. Rise. Grind. Repeat. About Grind Oral Care LLC Grind Oral Care is dedicated to creating safe, natural, great tasting and extremely effective oral care products designed to combat oral care problems. Extraordinary products backed by science to deliver results, while inspiring others to get after it, grind and never quit. Facebook/Twitter/Instagram/TikTok: @grindoralcare View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005993/en/ CONTACT: Roger L Gindlesperger Jr Grind Oral Care LLC 360-951-3260 [email protected] KEYWORD: UNITED STATES NORTH AMERICA UTAH INDUSTRY KEYWORD: WOMEN DISCOUNT/VARIETY DEPARTMENT STORES SPORTS MEN OTHER RETAIL FAMILY SUPERMARKET SPECIALTY CONSUMER GENERAL SPORTS RETAIL TEENS DENTAL CONVENIENCE STORE FOOTBALL HOME GOODS HEALTH OTHER CONSUMER ONLINE RETAIL SOURCE: Grind Oral Care Copyright Business Wire 2021. PUB: 02/09/2021 12:19 PM/DISC: 02/09/2021 12:19 PM http://www.businesswire.com/news/home/20210209005993/en WhatsApp Twitter NFL Veteran, Marques Ogden, Joins Forces With an Army Veteran and Grind Oral Care to Launch a Game-Changing Toothpaste Pinterestcenter_img WhatsApp Previous articleAffidavit: video surveillance shows fatal shootingNext articleOAT021021_Fog_wildart_jf_04.jpg Digital AIM Web Support Facebook Facebook TAGS  Pinterestlast_img read more

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings

first_img Facebook Pinterest Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings Twitter By Digital AIM Web Support – February 16, 2021 Pinterest HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. (“Iterion”), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has raised $17 million USD in a Series B financing led by Lumira Ventures, with the participation of existing investors, including Santé Ventures, as well as new investors Venture Investors, GPG Ventures, and Viva BioInnovator. Iterion plans to utilize the proceeds from this financing to advance the development of its lead clinical candidate, Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor. Tegavivint is currently being investigated in a Phase 1/2a clinical trial in patients with desmoid tumors, which are rare, non-metastasizing sarcomas that overexpress nuclear beta-catenin. Iterion has received Orphan Drug Designation for Tegavivint to treat desmoid tumors, a disease for which there are no FDA approved therapies. In addition to desmoid tumors, Iterion is preparing to initiate clinical programs in 2021 to investigate Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. These cancers are often characterized by nuclear beta-catenin overexpression, providing potential high-value target expansions for Tegavivint. “We envision incredible potential therapeutic benefits associated with Tegavivint, and are excited to support the Iterion team in its exploration of multiple clinical development opportunities for this potentially groundbreaking therapeutic,” said Benjamin Rovinski, Ph.D., Managing Director at Lumira Ventures. “2021 is expected to be a pivotal year for Iterion as the company anticipates initiating clinical trials in AML, NSCLC and pediatric cancers, all indications in which nuclear beta-catenin signaling plays a role. By pursuing a novel mechanism of action, we believe Tegavivint has the potential to overcome challenges faced by prior drugs targeting this pathway.” Nuclear beta-catenin is a highly-studied oncology target associated with numerous cancer types. Tegavivint is unique among nuclear beta-catenin inhibitors in that it binds to TBL1 (Transducin Beta-like Protein One), a novel downstream target in the Wnt-signaling pathway. As such, Tegavivint enables silencing of Wnt-pathway gene expression without affecting other necessary Wnt/beta-catenin functions in the cell membrane, thus avoiding toxicity issues common to other drugs in this pathway. “We are grateful to have the confidence of investors, including Lumira Ventures, Santé Ventures and others, that appreciate Tegavivint’s potential to treat a host of cancers,” said Rahul Aras, Ph.D., CEO of Iterion. “Nuclear beta-catenin has historically been considered an ‘undruggable’ oncology target with prior inhibitors having been plagued by toxicity issues, greatly limiting their therapeutic use. Research suggests that these toxicity concerns can be negated by targeting TBL1, a novel downstream target in the Wnt-signaling pathway necessary for beta-catenin’s oncogenic activity. This is precisely Tegavivint’s mechanism of action and why we believe the technology holds such substantial promise.” Dr. Aras continued, “With the Series B funding, Iterion has the potential to significantly expand our clinical footprint through completion of our ongoing desmoid tumor study and initiate clinical trials in 2021 to investigate Tegavivint in AML, NSCLC, and certain pediatric cancers.” About Iterion Therapeutics Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of nuclear beta-catenin, a historically “undruggable” oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit https://iteriontherapeutics.com or follow the Company on Twitter and Linkedin. Tiberend Strategic Advisors, Inc.Ingrid Mezo (Media) 646-604-5150 [email protected] View original content to download multimedia: http://www.prnewswire.com/news-releases/iterion-therapeutics-secures-17-million-to-advance-development-of-tegavivint-in-multiple-tumor-settings-301228000.html SOURCE Iterion Therapeutics Local NewsBusinesscenter_img Twitter Previous articleWinning numbers drawn in ‘Two Step’ gameNext articleBringCom Completes Pan-African Fiber Ring Network Digital AIM Web Support Facebook TAGS  WhatsApp WhatsApplast_img read more

Basware Named a Leader in IDC MarketScape Procure-to-Pay Assessment

first_img Pinterest Twitter By Digital AIM Web Support – February 16, 2021 WhatsApp Previous articleAlbertsons Companies Announces Winners of First Own Brands Associate Choice AwardsNext articleGuided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering Digital AIM Web Support Twitter Basware Named a Leader in IDC MarketScape Procure-to-Pay Assessment Local NewsBusiness Facebook Facebook Pinterest WhatsApp TAGS  last_img read more

eQHealth Solutions Announces Appointment of General Counsel

first_img eQHealth Solutions Announces Appointment of General Counsel Brooke Duncan III, General Counsel, eQHealth Solutions Pinterest Facebook Twitter TAGS  WhatsApp Previous articleSaladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic AssayNext articleHospitals still ration medical N95 masks as stockpiles swell Digital AIM Web Supportcenter_img Pinterest Twitter Facebook Local NewsBusiness WhatsApp By Digital AIM Web Support – February 16, 2021 last_img read more